Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Chronic Kidney Disease
100%
Myocardial Fibrosis
65%
T1 Time
44%
Myocardial T1
40%
Cardiac Magnetic Resonance Imaging (cMRI)
40%
Left Ventricular Mass
35%
Cardiac Magnetic Resonance
35%
Extracellular Volume
30%
Chronic Kidney Disease Stage
30%
Chlorthalidone
25%
Multi-parameter
25%
Early Chronic Kidney Disease
25%
Kidney Transplantation
25%
Premature Coronary Artery Disease
25%
Early Effect
25%
Spironolactone
25%
Myocardial Abnormalities
25%
Magnetic Resonance Imaging Study
25%
Transplantation
20%
End-stage Kidney Disease
20%
Uremic Cardiomyopathy
20%
T1 Mapping
15%
Late Gadolinium Enhancement
15%
Gadolinium-based Contrast Agents
15%
Cardiovascular Risk
10%
Cardiovascular Disease
10%
Once-daily
10%
Healthy Controls
10%
T2 Mapping
10%
Left Ventricular Hypertrophy
10%
Cardiovascular Mortality
10%
VO2peak
10%
Cardiovascular Function
10%
Aortic Distensibility
10%
Procollagen Type 1 N-terminal Propeptide (P1NP)
10%
Serum Biomarkers
10%
N-terminal Pro-brain Natriuretic Peptide (NT-proBNP)
10%
CT Coronary Calcium
5%
CT Coronary Angiography
5%
Change in eGFR
5%
Myocardial Structure
5%
Myocardial Disease
5%
Stable Measures
5%
Interstitial Edema
5%
Nephrogenic Systemic Fibrosis
5%
Left Atrial Dilatation
5%
Myocardial Remodeling
5%
Myocardial T2
5%
Effort Tolerance
5%
Left Ventricular Afterload
5%
Wave Change
5%
Mitral
5%
Ejection Fraction
5%
Recruitment Rate
5%
Angiotensin-converting Enzyme Inhibitor (ACEi)
5%
Disease-associated
5%
Focal Segmental Glomerulosclerosis
5%
Excess Risk
5%
High Risk
5%
Applanation Tonometry
5%
Disease Control
5%
Scar
5%
Native T1 Time
5%
LV Volume
5%
Atheroma
5%
Renal Function
5%
Pulse Wave Velocity
5%
Inflammation
5%
Coronary Artery Calcium Score
5%
Myocardial Hypertrophy
5%
Arterial Stiffness
5%
Myocardial Function
5%
Major Risk Factors
5%
Nonflow
5%
Statins
5%
Co-primary
5%
LV Mass Index
5%
ShMOLLI
5%
Cardiovascular Events
5%
Blood Pressure Control
5%
Blood Pressure Lowering
5%
MOLLI
5%
Kidney Disease
5%
24-h Ambulatory Blood Pressure Monitoring
5%
Placebo
5%
Clinical Trials
5%
Angiotensin Receptor Blockers
5%
Coronary Artery Disease
5%
Prospective Randomized Trial
5%
Coronary Artery
5%
Pathophysiology
5%
Treatment Options
5%
Cardiovascular Morbidity
5%
Myocardial Edema
5%
LV Mass
5%
Cardiomyopathy
5%
Drug Therapy
5%
Global Longitudinal Strain
5%
Volume Status
5%
Reduced Volume
5%
Mass Volume
5%
Cardiovascular Magnetic Resonance Imaging
5%
Clinically Insignificant
5%
Blood Pressure
5%
Cardiopulmonary Exercise Testing
5%
Excess Mortality
5%
Exercise Echocardiography
5%
Left Atrial Volume
5%
Heart Failure
5%
Left Ventricular Fibrosis
5%
Exercise Tolerance
5%
Estimated Glomerular Filtration Rate
5%
Functional Correlates
5%
Myocardial Dysfunction
5%
Fibrosis
5%
Troponin
5%
Collagen Turnover
5%
Non-invasive Biomarkers
5%
High-sensitivity Troponin T
5%
Pre-dialysis
5%
Strong Predictor
5%
Diffuse Fibrosis
5%
Multivariable Linear Regression Model
5%
Myocardial Ischemia
5%
Hypertension
5%
Myocardial Injury
5%
Edema
5%
Non-diabetic
5%
Echocardiography
5%
Medicine and Dentistry
Chronic Kidney Disease
87%
Cardiac Magnetic Resonance Imaging
58%
Cardiac Fibrosis
39%
Gadolinium
29%
Coronary Artery Disease
25%
Idiopathic Pulmonary Fibrosis
25%
Prematurity
25%
End Stage Renal Disease
25%
Kidney Transplantation
25%
Myocardial Disease
21%
Contrast Medium
18%
Edema
15%
Biological Marker
12%
Cardiovascular System
10%
Cardiovascular Risk
10%
Fibrosis
9%
Cardiovascular Disease
8%
Left Ventricular Hypertrophy
8%
Prochloraz
6%
Nephrogenic Systemic Fibrosis
6%
Natriuretic Factor
6%
Amino Terminal Sequence
6%
Echocardiography
6%
Cardiovascular Performance
6%
Troponin T
6%
Blood Pressure
5%
Isotopes of Calcium
5%
Statin
5%
Pathophysiology
5%
Focal Segmental Glomerulosclerosis
5%
Scar Formation
5%
Coronary Artery
5%
Ventricular Hypertrophy
5%
Pressure Control
5%
Angiography
5%